Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology.


Journal Article

While the clinical and neuropathological characterization of Alzheimer's Disease (AD) is well defined, our understanding of the progression of pathologic mechanisms in AD remains unclear. Post-mortem brains from individuals who did not fulfill clinical criteria for AD may still demonstrate measurable levels of AD pathologies to suggest that they may have presented with clinical symptoms had they lived longer or are able to stave off disease progression. Comparison between such individuals and those clinically diagnosed and pathologically confirmed to have AD will be key in delineating AD pathogenesis and neuroprotection. In this study, we expression profiled laser capture microdissected non-tangle bearing neurons in 6 post-mortem brain regions that are differentially affected in the AD brain from 10 non-demented individuals demonstrating intermediate AD neuropathologies (NDAD; Braak stage of II through IV and CERAD rating of moderate to frequent) and evaluated this data against that from individuals who have been diagnosed with late onset AD as well as healthy elderly controls. We identified common statistically significant expression changes in both NDAD and AD brains that may establish a degenerative link between the two cohorts, in addition to NDAD specific transcriptomic changes. These findings pinpoint novel targets for developing earlier diagnostics and preventative therapies for AD prior to diagnosis of probable AD. We also provide this high-quality, low post-mortem interval (PMI), cell-specific, and region-specific NDAD/AD reference data set to the community as a public resource.

Full Text

Cited Authors

  • Liang, WS; Dunckley, T; Beach, TG; Grover, A; Mastroeni, D; Ramsey, K; Caselli, RJ; Kukull, WA; McKeel, D; Morris, JC; Hulette, CM; Schmechel, D; Reiman, EM; Rogers, J; Stephan, DA

Published Date

  • April 2010

Published In

Volume / Issue

  • 31 / 4

Start / End Page

  • 549 - 566

PubMed ID

  • 18572275

Pubmed Central ID

  • 18572275

Electronic International Standard Serial Number (EISSN)

  • 1558-1497

Digital Object Identifier (DOI)

  • 10.1016/j.neurobiolaging.2008.05.013


  • eng

Conference Location

  • United States